Latest:

Fat Pitch Financials

Special situation stocks and value investing

Stock Quote

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Ardelyx Inc (NQ: ARDX )

5.120 USD -0.160 (-3.03%)
Official Closing Price Updated: 4:13 PM EDT, Oct 21, 2020 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 380,600
Open 5.240
Bid (Size) 5.100 (1)
Ask (Size) 5.850 (20)
Prev. Close 5.280
Today's Range 5.070 - 5.340
52wk Range 4.220 - 8.815
Shares Outstanding 60,103,568
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Ardelyx Announces Data Supporting Efficacy and Safety of Tenapanor, a First-in-Class Phosphate Absorption Inhibitor, to be Presented at ASN's Kidney Week 2020
--Comprehensive datasets demonstrate tenapanor's ability to control serum phosphorous in patients with chronic kidney disease (CKD) on dialysis-- 
From PR Newswire
Ardelyx Announces FDA Acceptance for Filing of its New Drug Application of Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis
NDA Supported by Data from Expansive Clinical Development Program Demonstrating Tenapanor's use as Foundational Therapy 
From PR Newswire

Performance

YTD
-30.34%
-30.34%
1 Month
-10.65%
-10.65%
3 Month
-23.98%
-23.98%
6 Month
-24.93%
-24.93%
1 Year
+1.99%
+1.99%

More News

Read More
Ardelyx to Participate in Three Upcoming Investor Conferences in September
From PR Newswire
Ardelyx Reports Second Quarter 2020 Financial Results and Recent Business Highlights
From PR Newswire
Ardelyx Selected as a Finalist in the Fierce Innovation Awards for the Development of its First-in-Class Product Candidate Tenapanor
From PR Newswire
Ardelyx Announces Submission of New Drug Application to the U.S. FDA for Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis
From PR Newswire
Ardelyx Announces Positive Second Data Analysis from Ongoing NORMALIZE Phase 4 Study Evaluating Tenapanor in CKD Patients on Dialysis
From PR Newswire
Ardelyx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From PR Newswire
Ardelyx Appoints Veteran Biopharma Executive, Justin Renz, as Chief Financial Officer
From PR Newswire
Ardelyx to Present at the Jefferies 2020 Virtual Healthcare Conference
From PR Newswire
Ardelyx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From PR Newswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.